Overview of Aderogil

Aderogil is a combination pharmaceutical preparation classified as an essential Vitamin Preparation and Nutritional Supplement that provides a foundational supply of two key fat-soluble vitamins simultaneously.

Quick Facts	Description
Active Ingredients	Colecalciferol (Vitamin D3), Vitamin A (Retinol)
Form	Oral Solution (Liquid), Oral Ampoules
Pharmacological Class	Fat-Soluble Vitamin Compound
General Purpose	Supplementation of essential nutrients for general health
Origin	Synthesized and purified from natural/synthetic precursors

What Type of Preparation is Aderogil?

Aderogil is a specialized combination pharmaceutical preparation belonging to the Fat-Soluble Vitamin Compound class, typically marketed in several international regions and designated for oral administration. The product is frequently supplied as an Oral Solution or in liquid Ampoules, a dosage form often utilized to facilitate the administration of nutrients to a broad population, including children. Colecalciferol's role as a pro-hormone relates to its functional relationship with calcium regulation. Consequently, the medicine's core component is recognized as essential for systemic mineral balance.

Composition and Formulation: Colecalciferol and Vitamin A

The active ingredients in Aderogil are Colecalciferol (Vitamin D3) and Vitamin A (Retinol or an ester thereof), both recognized as essential nutrients. A distinguishing factor is its liquid Oral Solution formulation, which utilizes a specific vehicle to maximize the absorption of its fat-soluble components. The fat-soluble nature of both components is key to the overall design of the product. Vitamin A plays a role in normal growth, vision, and immune function, specifically in maintaining the integrity of epithelial cells. This highlights that the compound’s dual composition directly supports several distinct, critical body systems.

General Benefit and Purpose of the Essential Nutrient Compound

The general purpose of Aderogil is to serve as a nutritional supplement to prevent or correct established deficiencies of these two essential nutrients. Colecalciferol is critical for supporting strong bone development and density, while Vitamin A maintains normal vision and aids the healthy state of epithelial tissues. A typical, neutral use scenario involves the prophylactic supplementation of children during periods of rapid growth. The compound’s benefit is its combined role in ensuring the sustained availability of these vital cofactors for metabolic and structural processes.

Regulatory References

WHO Vitamin A Deficiency Data

What side effects are possible with Aderogil?

Possible Side Effects and Safety Information

The official safety profile for Aderogil, a combination of the fat-soluble vitamins Colecalciferol (Vitamin D3) and Vitamin A (Retinol), is primarily structured around the risk of Hypervitaminosis (toxicity) resulting from excessive accumulation. Adverse reactions are grouped by the body systems they affect, as classified in government regulatory documents.

Adverse Reaction Classification

System-Organ Class	Examples of Documented Adverse Reactions
Metabolism and Nutrition	Hypercalcaemia (excess calcium in the blood), Hypercalciuria (excess calcium in the urine), loss of appetite.
Gastrointestinal Disorders	Nausea, vomiting, abdominal pain, and constipation.
Nervous System Disorders	Headache, lethargy, and drowsiness.

Serious Adverse Reactions and Risk Context

Adverse reactions associated with toxicity are generally uncommon and reflect the consequences of chronic, prolonged, and excessive intake. The most serious adverse reactions documented in regulatory sources include Renal Failure, secondary to severe Hypercalcaemia, as well as soft tissue calcification and severe neurological effects such as signs of increased intracranial pressure (associated with Vitamin A toxicity).

This compound is officially contraindicated in individuals with pre-existing conditions like Hypercalcaemia and Nephrolithiasis (kidney stones). Additionally, official labels contain specific warnings regarding the potential teratogenic risk (risk of birth defects) associated with high doses of Vitamin A for pregnant individuals. The safety framework emphasizes these limitations and restrictions over its intended use.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Aderogil (Vitamin D, Cholecalciferol) results in a condition known as hypervitaminosis D, which leads to dangerously high levels of calcium in the blood (hypercalcaemia). This complication is the primary cause of overdose symptoms and potential organ damage.

Overdose Manifestations	Symptoms and Affected Systems
Early Symptoms	Loss of appetite, nausea, vomiting, constipation, weakness, fatigue, headache, and excessive thirst.
Systemic Effects	Hypercalcaemia can lead to polyuria, somnolence, vertigo, and an imbalance in bone metabolism.
Severe Complications	High calcium levels may result in the deposition of calcium in soft tissues, including the kidneys and blood vessels, potentially causing nephrocalcinosis and renal impairment or failure.

Overdose is typically associated with sustained intake of very high doses, significantly exceeding the recommended daily allowance, and is more likely in infants and children due to their increased susceptibility. Immediate medical attention is required if overdose is suspected or if symptoms suggesting hypercalcaemia, such as persistent vomiting, profound fatigue, or excessive urination and thirst, occur. In case of suspected toxicity, the product should be immediately withdrawn, and a healthcare provider must be contacted to monitor blood calcium and Vitamin D levels.

Therapeutic Uses of Aderogil

What Aderogil Treats: Main Uses and Benefits

Aderogil, a combination of Vitamin D3 (Colecalciferol) and Vitamin A (Retinol), is primarily relevant for supportive management in clinical settings marked by systemic imbalance due to essential nutritional deficits. Vitamin D plays a role in managing bone health, and persistent deficiency is associated with conditions such as rickets and osteoporosis. The preparation is considered relevant across multiple therapeutic domains, supporting bone, muscle, and systemic health.

Key Therapeutic Focus

Aderogil is applied across domains where additional symptomatic support is needed, primarily to address symptom clusters that may become intense or disruptive, such as bone pain and proximal muscle weakness linked to chronic deficiency. This supportive benefit helps maintain a sense of stability and assists with maintaining functional stability. The medication is also utilized in specific clinical scenarios, including periods of rapid childhood growth and for individuals with limited sun exposure or malabsorption syndromes.

The preparation plays a role in managing anticipated deficiency, which generally supports the patient during difficult episodes by easing the overall symptom load that can arise from chronic nutritional deficits.

Quick Fact: Relief for Musculoskeletal Strain
Common Use: Used to help manage bone tenderness and muscle weakness that interfere with daily comfort due to Vitamin D deficiency.

Regulatory References

NIH MedlinePlus overview of Vitamin D

Eligibility and Restrictions for Use

The eligibility profile for Aderogil (Colecalciferol and Vitamin A) is strictly defined by official regulatory documentation, prohibiting use in patients with pre-existing metabolic imbalances or specific clinical conditions. The medicine is contraindicated for individuals with Hypersensitivity to the active ingredients, Hypercalcaemia, Hypercalciuria, Hypervitaminosis D, or severe renal impairment. Patients with a tendency to form calcium-containing renal calculi are also advised against its use.

Use is restricted and requires caution for populations with Sarcoidosis or mild to moderate renal impairment, necessitating close monitoring of serum and urinary calcium levels.

Regarding age, use in infants and young children must be determined by a healthcare provider, and specific formulations are not intended for use in children under 12 years of age. Older adults require specific monitoring.

In physiological states, high doses of Vitamin A are not recommended or contraindicated during pregnancy due to teratogenic risk, and Vitamin D overdose must also be avoided. Use during lactation is restricted to low, monitored doses.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Administration and Exposure Restrictions

Due to the risk of excessive exposure and potential toxicity, co-administration of Aderogil is restricted with other high-dose vitamin D products, supplements, or metabolites. Timing rules apply to agents that interfere with fat absorption: the regulatory label requires administering lipase inhibitors, such as Orlistat, at least 2 hours apart from Aderogil to minimize reduction in the vitamin's gastrointestinal absorption.

Metabolic and Pharmacodynamic Interactions

Certain medicinal products are documented to accelerate the clearance of Colecalciferol (Vitamin D3). This pharmacokinetic interaction occurs with enzyme-inducing agents like some anticonvulsants (e.g., Phenytoin, Barbiturates) and antituberculosis agents (e.g., Rifampicin), which increase the hepatic catabolism of the vitamin, officially reducing its effectiveness.

Pharmacodynamic interactions primarily involve systemic mineral balance. Thiazide diuretics and high doses of calcium-containing products have an additive effect with Vitamin D, increasing the potential for hypercalcaemia. This hypercalcaemia, if it occurs, enhances the cardiotoxic effects of cardiac glycosides (e.g., Digitalis). Caution is also advised regarding the combination with magnesium-containing products, which may increase the risk of hypermagnesaemia. Population-specific notes require the monitoring of Vitamin A levels in individuals with liver impairment or high alcohol intake.

Mechanism of Action

Aderogil's mechanism is based on the distinct actions of its primary active components, Vitamin A (Retinyl Acetate) and Vitamin D3 (Cholecalciferol). The retinyl component acts as a ligand for retinoic acid receptors (RARs) and retinoid X receptors (RXRs). Upon binding to these nuclear transcription factors, it modulates the expression of genes involved in cellular differentiation, proliferation, and epithelial maintenance throughout various tissues.

The cholecalciferol component is metabolically converted in two hydroxylation steps—first in the liver by CYP2R1 to 25-hydroxyvitamin D, and then primarily in the kidney by CYP27B1 to the hormonally active calcitriol (1,25-dihydroxyvitamin D). Calcitriol acts as a high-affinity ligand for the Vitamin D Receptor (VDR), another nuclear receptor. VDR activation leads to the transcriptional control of hundreds of genes, notably those regulating the absorption of calcium and phosphate in the intestine and the regulation of bone remodeling units. The combined actions of these ligands on their respective nuclear receptors influence systemic processes, including calcium homeostasis and cellular growth cycles, via genomic and non-genomic signal transduction.

Dosage and Administration Information

How to Use Aderogil: Official Administration Guidelines

Aderogil is a combination vitamin preparation supplied as an Oral Solution or in liquid Ampoules. The official instructions for its use are structured around a clear dosing protocol and specific administration conditions, consistent with standard clinical practice for its fat-soluble vitamin components.

Administration Scope

Category	Instruction
Route of administration	The designated administration route is Oral (swallowing the solution).
Dosing schedule	The regimen is divided: an initial treatment phase (e.g., up to 4,000 IU daily of Colecalciferol for a fixed period) followed by a maintenance phase (typically 800 IU to 2,000 IU daily).
Timing in relation to meals	The solution may be taken once daily, and administration is permitted with or without food.
Preparation requirements	The exact dose must be measured using the calibrated measuring device (syringe or dropper) provided in the pack to ensure accuracy.
Age-group administration rules	Dosage adjustments are specified, such as a range of 500 IU to 2,000 IU per day for adolescents. Use is restricted in patients with severe renal impairment.
Missed-dose rules	If an administration is missed, standard protocol suggests the patient should not take a double dose to compensate.
Special procedural conditions	The solution may be mixed with a small amount of cold or lukewarm food or beverage to facilitate intake.

Resulting Procedural Structure

The usage protocol mandates a transition from a short-term corrective course to a long-term prophylactic maintenance regimen. This structure ensures that the medicine is consistently administered via the Oral route, with the daily dose precisely measured and consumed in accordance with age and health-specific rules.

Recent Clinical Evidence

Research evidence / Overview of Studies for Aderogil

The research base for Aderogil, a combination of Vitamin D3 (Colecalciferol) and Vitamin A (Retinol), is founded on the extensive evidence surrounding the two essential nutrients individually, with some specific research exploring their combined use. This overview summarizes the structure of the evidence and the findings observed in these studies.

Evidence for Deficiency Correction and Prevention

Researchers conducted a large number of Randomized Controlled Trials (RCTs) and Systematic Reviews to examine the ability of the vitamins to change established low vitamin levels in the blood. These studies primarily targeted Vitamin D's role in bone health and mineral balance, and Vitamin A's role in vision and the integrity of epithelial cells. The study outcomes examined included the maintenance or correction of serum 25-hydroxyvitamin D [25(OH)D] biomarker concentrations and the incidence of deficiency-related skeletal diseases, such as rickets in children.

Studies reported measured changes in serum 25(OH)D levels in deficient individuals. Some trials reported a reduced incidence of rickets in children receiving supplementation compared to control groups. However, heterogeneity in trial designs across large-scale studies evaluating Vitamin D's effect on fracture incidence have led to inconsistent findings, making the overall pattern difficult to summarize broadly.

Research on Supportive Management During Growth and Development

Studies used RCTs and Longitudinal Follow-up Studies to observe populations like infants and children during periods characterized by rapid growth. These studies examined outcomes such as measures of linear growth, changes in markers of bone mineral accretion, and examined the prevention of rickets. While studies observed patterns related to the prevention of rickets, research highlights that changes measured during the study period for overall linear growth showed high variability across different studies. Data that definitively isolate the impact of the simultaneous combination of Vitamin A and Vitamin D on growth outcomes remains insufficient.

Research Gaps and Uncertainties

Significant research gaps and uncertainties persist across the body of evidence. A primary limitation is the lack of head-to-head comparative evidence for the specific, fixed Aderogil combination product against single-vitamin therapies across all patient groups. Furthermore, follow-up durations were limited in many studies focusing on symptom resolution, and long-term effects are not fully established for the durability of benefits over many years, particularly in non-skeletal domains.

Key Studies & References

Vitamin D (MedlinePlus Overview - National Library of Medicine/NIH)

Frequently Asked Questions (FAQ)

Common questions about Aderogil (FAQ)

Q: Why is Aderogil sometimes used during certain seasons?

Official information regarding the Vitamin D3 component indicates its purpose is to correct vitamin deficiencies. Since Vitamin D levels are commonly associated with reduced exposure to sunlight, the use of this preparation often reflects common clinical observation of deficiencies during periods of reduced sunlight.

Q: How quickly do people usually notice the effects of Aderogil?

Research and official documents related to the active components measure effectiveness by tracking changes in specific biomarkers, such as the serum levels of 25-hydroxyvitamin D. Changes in these measurable laboratory markers may take several weeks for these measured biomarker changes to be observed.

Q: How long does the effect of one dose of Aderogil last?

Aderogil contains fat-soluble vitamins, which means the components are held in the body's tissues, meaning the effects can persist beyond immediate administration. This characteristic supports the structure of the product's long-term maintenance protocols.

Q: Are there any common foods or drinks that should be avoided when using Aderogil?

Official documents advise that the solution is permitted to be taken with or without food. However, regulatory instructions require that certain medications that interfere with fat absorption, such as Orlistat, be administered at least two hours apart from Aderogil to prevent reduced absorption.

Q: Does Aderogil interact with birth control pills?

Regulatory documents list specific drug classes, such as certain enzyme-inducing agents like anticonvulsants, that can interact with Aderogil and potentially speed up the clearance of the Vitamin D3 component. A specific warning regarding oral contraceptives is not noted in the official interaction profile provided.

Q: Is Aderogil considered a high-dose supplement?

The official safety profile for the fat-soluble vitamins in Aderogil emphasizes the potential risk of Hypervitaminosis, or toxicity, which results from chronic, prolonged, and excessive intake. Because of this risk, the required dosage regimen is structured to strictly control intake and avoid exceeding established limits.

Q: Does taking Aderogil require any changes to one's normal diet?

Official administration rules state that the product is permitted to be taken with or without food. However, regulatory sources restrict the use of Aderogil simultaneously with other high-dose Vitamin D products or supplements due to the risk of excessive exposure.

Q: Can Aderogil be used for general 'tiredness' or fatigue?

The general purpose described in official texts is to prevent or correct established deficiencies of Vitamin A and Vitamin D, which support bone health, vision, and epithelial tissues. The document does not describe the use of this compound for addressing general tiredness or fatigue.

Q: Is it true that Aderogil is often taken with a meal?

The official administration guidelines for Aderogil state that the solution is permitted to be taken once daily, with or without food. The solution can also be mixed with a small amount of cold or lukewarm food to facilitate administration.

Q: Is Aderogil known to cause stomach upset or digestive issues?

Documented adverse reactions in the official safety profile include Gastrointestinal Disorders. Examples listed are nausea, vomiting, abdominal pain, and constipation.

Q: Are there specific age limits for who can use Aderogil?

Official restrictions state that use in infants and young children must be determined by a healthcare provider. Specific formulations of the medicine are not intended for use in children under 12 years of age.

Q: Is it possible for Aderogil to make you feel restless or affect sleep?

Adverse reactions related to the Nervous System are documented and include effects such as headache, lethargy, and drowsiness. Restlessness or specific sleep effects are not mentioned in the listed adverse reactions related to the Nervous System.

Q: Does Aderogil affect blood pressure readings?

Official interaction warnings note that certain medications, such as thiazide diuretics (often used to treat high blood pressure), have an additive effect with the Vitamin D component. This combination increases the potential for Hypercalcaemia (excess calcium in the blood).

Q: Is it safe to use Aderogil for an extended period?

The usage protocol includes a transition to a long-term prophylactic maintenance regimen. However, the safety profile emphasizes the risk of toxicity (Hypervitaminosis) that results from chronic, prolonged, and excessive intake. Close adherence to the prescribed regimen is described as important due to this risk.

Q: Is Aderogil primarily for a short-term or long-term course of use?

The official usage protocol mandates a procedural transition. This involves starting with a short-term corrective course, followed by a switch to a long-term prophylactic maintenance regimen.

Q: How do the ingredients in Aderogil relate to immune system function?

The World Health Organization confirms that one of the active components, Vitamin A, is vital for normal growth and aids in the healthy state of epithelial cells and immune system function. The compound’s dual composition supports these distinct, critical body systems.

Q: What does 'use conditions' for Aderogil mean in official documents?

In regulatory documents, 'use conditions' refers to the formal administration rules for the medicine. These rules encompass the approved administration route (oral), the required dosing schedule structure, timing in relation to meals, and specific age-group administration rules.

Q: Can Aderogil be taken at the same time as cold and flu medicine?

Regulatory documents list specific restricted drug classes that can interact with Aderogil. Because regulatory documents list specific restricted drug classes, the compatibility with combined active ingredients in cold and flu medicines is often a topic for discussion with a healthcare provider.

Q: Does Aderogil interact with thyroid medications?

Regulatory documents state that certain enzyme-inducing agents accelerate the clearance of the Vitamin D3 component, which reduces its effectiveness in the body. This pharmacokinetic interaction could potentially involve some older thyroid-related drugs or similar medications.

Q: What happens if I stop using Aderogil suddenly?

The general purpose of the preparation is to prevent or correct established vitamin deficiencies. Stopping the product may result in the gradual return of the deficient state the product was intended to address, potentially leading to a decline in serum vitamin levels over time.

How should Aderogil be stored and disposed of?

How to Store and Dispose of Aderogil

Official regulatory labeling dictates strict conditions for storing Aderogil, an oral solution containing fat-soluble vitamins, to ensure stability.

Storage Requirements

The medicine must be stored at a temperature below 25°C (77°F). It is mandatory to protect Aderogil from both light and moisture, and the labeling explicitly states do not put in the refrigerator or freeze the product. The solution must be kept in its original container with the cap tightly closed. For multi-dose bottles, the content must be used within 3 months after the first opening.

Disposal Instructions

As with most pharmaceutical products, Aderogil must be kept out of the sight and reach of children.

Unused or expired product should not be disposed of in wastewater or household trash. Patients are required to ask a pharmacist for the proper method of disposal, ensuring the medicine is handled as pharmaceutical waste according to local environmental regulations.

Aderogil